Global First-in-Class AT2R Antagonist TRD205 Advances to Phase II: First Patient Dosed in Chronic Post-Surgical Neuropathic Pain Trial ...Middle East

BEIJING, May 5, 2025 /PRNewswire/ -- Beijing Tide Pharmaceutical Co., Ltd., a subsidiary of Sino Biopharmaceutical Limited (1177.HK), has achieved a milestone in developing its first-in-class analgesic drug (research code: TRD205), a highly selective angiotensin II type 2 receptor (AT2R)...

Read More Details
Finally We wish PressBee provided you with enough information of ( Global First-in-Class AT2R Antagonist TRD205 Advances to Phase II: First Patient Dosed in Chronic Post-Surgical Neuropathic Pain Trial )

Also on site :

• Emmy Predictions: Talk/Scripted Variety Series — The Variety Categories Are Still a Mess; Netflix, Dropout, and ‘Hot Ones’ Stir Up Buzz
• Ex-Bellingcat child porn researcher commits suicide after conviction for abusing own child – media
• Khloe Kardashian and Podcaster Totally Gush Over Each Other and Fans Are Swooning